EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Safety of secondary CRS/HIPEC in peritoneal surface malignancies: Insights from a national cohort study

Lukas Pollmann, Jürgen Zieren, Nicola S Pollmann, Urs Giger-Pabst, Pompiliu Piso, Michael Ströhlein, Nicola Cerasani, Fabian Kockelmann, Maximilian Schmeding, members of the StuDoQ|HIPEC registry of the German Society for General and Visceral Surgery (DGAV)

European Journal of Surgical Oncology · 2026

DOI: 10.1016/j.ejso.2026.111408 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift European Journal of Surgical Oncology, 2026. Verfasst von Lukas Pollmann und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General and Visceral Surgery, Witten/Herdecke University, Klinikum Dortmund gGmbH, Germany. Electronic address: Pollmann.lukas@yahoo.de. Hauptthemen laut MEDLINE: Peritoneal Neoplasms, Cytoreduction Surgical Procedures, Hyperthermic Intraperitoneal Chemotherapy, Reoperation. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: For carefully selected patients with peritoneal surface malignancies (PSMs), secondary cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) can provide similar oncological results as primary CRS/HIPEC. However, the mortality rate and the incidence of reoperations due to perioperative complications after secondary CRS/HIPEC remain understudied. METHODS: A retrospective analysis was conducted using the StuDoQ|HIPEC registry, a prospectively maintained national German CRS/HIPEC database, to compare reoperation rates and 30-day mortality between patients undergoing primary and secondary CRS/HIPEC. The analysis included patients treated at 83 centers between 2011 and 2024. Propensity-score matching was performed to adjust for confounding factors prior to comparing outcomes between the matched cohorts. RESULTS: A comprehensive analysis of 5011 primary CRS/HIPEC cases and 236 secondary CRS/HIPEC cases showed no significant differences in reoperation rates (15 % vs. 12 %, p = 0.192) or 30-day mortality (2 % vs. 1 %, p = 0.240). After propensity-score matching to control for confounding factors, outcomes remained comparable, with identical reoperation rates of 12 % in both groups (p = 1.000) and similar 30-day mortality (2 % vs. 1 %, p = 0.685). Within the secondary CRS/HIPEC group, the male-to-female ratio was 1:3, and the median age was 55 years. The majority of these patients underwent secondary CRS/HIPEC primarily for appendiceal cancer (27 %), pseudomyxoma peritonei (21 %), or colorectal cancer (20 %), mesothelioma (12 %) and ovarian cancer (10 %). CONCLUSIONS: Secondary CRS/HIPEC can be performed safely in selected patients with PSMs, comparable to primary CRS/HIPEC. Reoperation rates and 30-day mortality rates were similar between groups, even after adjusting for confounding factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peritoneal NeoplasmsCytoreduction Surgical ProceduresHyperthermic Intraperitoneal ChemotherapyReoperationHumansFemaleMaleMiddle AgedRetrospective StudiesPropensity ScoreAgedRegistriesOvarian NeoplasmsPostoperative ComplicationsGermanyPseudomyxoma PeritoneiAdultAppendiceal NeoplasmsMesotheliomaColorectal Neoplasms

Stichwörter der Autor:innen

Cytoreductive surgery (CRS)Hyperthermic intraperitoneal chemotherapy (HIPEC)Peritoneal surface malignancies (PSM)Propensity-score matchingReoperation rate

Autor:innen und Institutionen

  • Department of General and Visceral Surgery, Witten/Herdecke University, Klinikum Dortmund gGmbH, Germany. Electronic address: Pollmann.lukas@yahoo.de.
  • Department of General and Visceral Surgery, Witten/Herdecke University, Klinikum Dortmund gGmbH, Germany.
  • Department of General-, Visceral and Transplant Surgery, University Hospital Jena, Germany.
  • Fliedner Fachhochschule, University of Applied Sciences Düsseldorf, Germany; UMR1327 ISCHEMIA "Membrane Signalling and Inflammation in Reperfusion Injuries", Université de Tours, Tours, France.
  • Department of General and Visceral Surgery, Hospital Barmherzige Brüder, Regensburg, Germany.
  • Department of Abdominal, Vascular and Transplant Surgery, Merheim Medical Center, Witten/Herdecke University, Cologne, Germany.

Zitieren

APA

Pollmann, L., Zieren, J., Pollmann, N. S., Giger-Pabst, U., Piso, P., Ströhlein, M., Cerasani, N., Kockelmann, F., Schmeding, M., & members of the StuDoQ|HIPEC registry of the German Society for General and Visceral Surgery (DGAV) (2026). Safety of secondary CRS/HIPEC in peritoneal surface malignancies: Insights from a national cohort study. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2026.111408

Vancouver

Pollmann L, Zieren J, Pollmann NS, Giger-Pabst U, Piso P, Ströhlein M, et al. Safety of secondary CRS/HIPEC in peritoneal surface malignancies: Insights from a national cohort study. European Journal of Surgical Oncology. 2026. doi:10.1016/j.ejso.2026.111408

BibTeX
@article{Pollmann2026,
  author = {Pollmann, Lukas and Zieren, Jürgen and Pollmann, Nicola S and Giger-Pabst, Urs and Piso, Pompiliu and Ströhlein, Michael and Cerasani, Nicola and Kockelmann, Fabian and Schmeding, Maximilian and members of the StuDoQ|HIPEC registry of the German Society for General and Visceral Surgery (DGAV), members of the StuDoQ|HIPEC registry of the German Society for General and Visceral Surgery (DGAV)},
  title = {Safety of secondary CRS/HIPEC in peritoneal surface malignancies: Insights from a national cohort study},
  journal = {European Journal of Surgical Oncology},
  year = {2026},
  doi = {10.1016/j.ejso.2026.111408}
}
Kostenlos starten →